Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- PMID: 39953460
- PMCID: PMC11829406
- DOI: 10.1186/s12885-025-13606-1
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Abstract
Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for selected patients. The purpose of this study was to thoroughly examine the impact of the combined treatment and the prognostic variables, particularly the neutrophil-to-lymphocyte ratio (NLR).
Methods: Characteristics of MPM patients who underwent CRS combined HIPEC treatment, followed by adjuvant chemotherapy were retrospectively collected. The univariable analysis was performed to identify the decisive influential factor. Using Kaplan-Meier analysis, the cumulative probability of survival was determined. Using Univariate Cox analysis, the prognostic factors-particularly NLR-and its correlation with survival were assessed. In the multivariate Cox proportional hazards model, predictive factors that demonstrated significance in univariate analysis were used. The degree of connection between predictors and survival was evaluated through the use of hazard ratios (HRs) and 95% confidence intervals (95% CIs).
Results: A total of 64 patients were enrolled in this study. The 1, 3, 5 years survival rates were 70.3%, 65.6%, 59.4%, respectively. According to multivariate Cox analysis, patients' survival was found to be substantially associated with post-operative NLR (HR 0.180, 0.067-0.531), Ki-67 (HR 0.184, 0.024-0.817), post-operative neutrophil count (HR 0.228, 0.075-0.696), and bidirectional pathological type (HR, 0.375, 0.146-0.964).
Conclusions: NLR is associated with the patients' prognosis after CRS combined HIPEC treatment.
Keywords: Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy; Malignant Peritoneal Mesothelioma; Neutrophil-to-Lymphocyte Ratio; Prognosis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study adhered to the Declaration of Helsinki and was approved by the ethic committee of Beijing Shijitan Hospital, Capital Medical University. Written informed consent was obtained from all the participants for the publication of this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.Ann Surg Oncol. 2025 Apr;32(4):2912-2922. doi: 10.1245/s10434-024-16485-1. Epub 2024 Nov 13. Ann Surg Oncol. 2025. PMID: 39538101
-
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.Ann Surg Oncol. 2015 May;22(5):1680-5. doi: 10.1245/s10434-014-3977-y. Epub 2014 Aug 14. Ann Surg Oncol. 2015. PMID: 25120250
-
Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study.Eur J Surg Oncol. 2024 Nov;50(11):108692. doi: 10.1016/j.ejso.2024.108692. Epub 2024 Sep 14. Eur J Surg Oncol. 2024. PMID: 39298871
-
Perfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.J Surg Oncol. 2025 Feb;131(2):310-315. doi: 10.1002/jso.27882. Epub 2024 Sep 10. J Surg Oncol. 2025. PMID: 39257167 Review.
-
Systemic Therapy and Surgical Management of Peritoneal Mesothelioma.Surg Oncol Clin N Am. 2025 Apr;34(2):253-263. doi: 10.1016/j.soc.2024.12.002. Epub 2025 Jan 7. Surg Oncol Clin N Am. 2025. PMID: 40015803 Review.
References
-
- Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60. - PubMed
-
- Chirac P, Maillet D, Leprêtre F, et al. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72–82. - PubMed
-
- Antman KH, Corson JM, Li FP, et al. Malignant mesothelioma following radiation exposure. J Clin Oncol. 1983;1(11):695–700. - PubMed
-
- Robella M, Vaira M, Mellano A, et al. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir. 2014;69(1):9–15. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical